 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 February 1999 | Volume 130 Issue 4 Part 1 | Pages 270-277
Background: The relation between endogenous steroid hormones and risk for breast cancer is uncertain. Measurement of sex hormone levels may identify women at high risk for breast cancer who should consider preventive therapies.
Objective: To test the hypothesis that serum concentrations of estradiol and testosterone predict risk for breast cancer.
Design: Prospective case-cohort study.
Setting: Four clinical centers in the United States.
Participants: 97 women with confirmed incident breast cancer and 244 randomly selected controls; all women were white, 65 years of age or older, and were not receiving estrogen.
Measurements: Sex-steroid hormone concentrations were assayed by using serum that was collected at baseline and stored at –190 °C. Risk factors for breast cancer were ascertained by questionnaire. Incident cases of breast cancer were confirmed by review of medical records during an average period of 3.2 years.
Results: The relative risk for breast cancer in women with the highest concentration of bioavailable estradiol (
Conclusions: Estradiol and testosterone levels may play important roles in the development of breast cancer in older women. A single measurement of bioavailable estradiol and free testosterone may be used to estimate a woman's risk for breast cancer. Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention.
Author and Article Information
From University of Pittsburgh, Pittsburgh, Pennsylvania; Maine Medical Center, Portland, Maine; University of California, San Francisco; and Veterans Affairs Medical Center, San Francisco, California.
Grant Support: In part by National Institutes of Health Public Health Service research grants AM35584, AR35582, AG05407, AG05395, AR35583, and TG32AG00181 and by grant DAMD17-96-6114 from the U.S. Army Medical Research and Material Command.
Requests for Reprints: Jane A. Cauley, DrPH, Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 130 DeSoto Street, Crabtree Hall A524, Pittsburgh, PA 15261.
Current Author Addresses: Drs. Cauley and Kuller: Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 130 DeSoto Street, Crabtree Hall A524, Pittsburgh, PA 15261.
Dr. Lucas: Health Services Research, Maine Medical Center, 31 Bramhall, Portland, ME 04102.
Drs. Stone, Browner, and Cummings: Department of Biostatistics and Epidemiology, University of California, 74 New Montgomery Street, Suite 600, San Francisco, CA 94105. ARTICLE
Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast Cancer
6.83 pmol/L or 1.9 pg/mL) was 3.6 (95% CI, 1.3 to 10.0) compared with women with the lowest concentration. The risk for breast cancer in women with the highest concentration of free testosterone compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). The estimated incidence of breast cancer per 1000 person-years was 0.4 (CI, 0.0 to 1.3) in women with the lowest levels of bioavailable estradiol and free testosterone compared with 6.5 (CI, 2.7 to 10.3) in women with the highest concentrations of these hormones. Traditional risk factors for breast cancer were similar in case-patients and controls. Adjustments for these risk factors had little effect on the results.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. B. Ness, J. D. Albano, A. McTiernan, and J. A. Cauley Influence of Estrogen Plus Testosterone Supplementation on Breast Cancer Arch Intern Med, January 12, 2009; 169(1): 41 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Braunstein, B. D. Johnson, F. Z. Stanczyk, V. Bittner, S. L. Berga, L. Shaw, T. K. Hodgson, M. Paul-Labrador, R. Azziz, and C. N. B. Merz Relations between Endogenous Androgens and Estrogens in Postmenopausal Women with Suspected Ischemic Heart Disease J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4268 - 4275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xiao, A. A. Powolny, and S. V. Singh Benzyl Isothiocyanate Targets Mitochondrial Respiratory Chain to Trigger Reactive Oxygen Species-dependent Apoptosis in Human Breast Cancer Cells J. Biol. Chem., October 31, 2008; 283(44): 30151 - 30163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Shufelt and G. D Braunstein Testosterone and the breast Menopause Int, September 1, 2008; 14(3): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W. Blank, P.-Y. Wong, R. Lakshmanaswamy, R. Guzman, and S. Nandi Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats PNAS, March 4, 2008; 105(9): 3527 - 3532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Xue and K. B Michels Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence Am. J. Clinical Nutrition, September 1, 2007; 86(3): 823S - 835S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lee, B. Ettinger, F. Z. Stanczyk, E. Vittinghoff, V. Hanes, J. A. Cauley, W. Chandler, J. Settlage, M. S. Beattie, E. Folkerd, et al. Comparison of Methods to Measure Low Serum Estradiol Levels in Postmenopausal Women J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3791 - 3797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian and B. F. Kimler Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials J. Nutr., October 1, 2006; 136(10): 2705S - 2708S. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Russo, S. V. Fernandez, P. A. Russo, R. Fernbaugh, F. S. Sheriff, H. M. Lareef, J. Garber, and I. H. Russo 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells FASEB J, August 1, 2006; 20(10): 1622 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Eliassen, S. A. Missmer, S. S. Tworoger, and S. E. Hankinson Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer: Does the Association Vary by a Woman's Predicted Breast Cancer Risk? J. Clin. Oncol., April 20, 2006; 24(12): 1823 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Vogel and E. Taioli Have We Found the Ultimate Risk Factor for Breast Cancer? J. Clin. Oncol., April 20, 2006; 24(12): 1791 - 1794. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Beattie, J. P. Costantino, S. R. Cummings, D. L. Wickerham, V. G. Vogel, M. Dowsett, E. J. Folkerd, W. C. Willett, N. Wolmark, and S. E. Hankinson Endogenous Sex Hormones, Breast Cancer Risk, and Tamoxifen Response: An Ancillary Study in the NSABP Breast Cancer Prevention Trial (P-1) J Natl Cancer Inst, January 18, 2006; 98(2): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Kaaks, S Rinaldi, T J Key, F Berrino, P H M Peeters, C Biessy, L Dossus, A Lukanova, S Bingham, K-T Khaw, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition Endocr. Relat. Cancer, December 1, 2005; 12(4): 1071 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wang, E. M. John, and S. A. Ingles Androgen Receptor and Prostate-Specific Antigen Gene Polymorphisms and Breast Cancer in African-American Women Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2990 - 2994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Nelson, L. H. Huffman, R. Fu, and E. L. Harris Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force Ann Intern Med, September 6, 2005; 143(5): 362 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cummings, J. S. Lee, L.-Y. Lui, K. Stone, B. M. Ljung, J. A. Cauleys, and for the Study of Osteoporotic Fractures Research G Sex Hormones, Risk Factors, and Risk of Estrogen Receptor-Positive Breast Cancer in Older Women: A Long-term Prospective Study Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1047 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Geisler and P. E. Lonning Aromatase Inhibition: Translation into a Successful Therapeutic Approach Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, F. Paris, C. S. Sultan, R. X.-D. Song, L. M. Demers, B. Sundaram, J. Settlage, S. Ohorodnik, and R. J. Santen Recombinant Cell Ultrasensitive Bioassay for Measurement of Estrogens in Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1407 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Lonning Exemestane for Breast Cancer Prevention: A Feasible Strategy? Clin. Cancer Res., January 15, 2005; 11(2): 918s - 924s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Martino, J. A. Cauley, E. Barrett-Connor, T. J. Powles, J. Mershon, D. Disch, R. J. Secrest, S. R. Cummings, and For the CORE Investigators Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene J Natl Cancer Inst, December 1, 2004; 96(23): 1751 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lepine, O. Bernard, M. Plante, B. Tetu, G. Pelletier, F. Labrie, A. Belanger, and C. Guillemette Specificity and Regioselectivity of the Conjugation of Estradiol, Estrone, and Their Catecholestrogen and Methoxyestrogen Metabolites by Human Uridine Diphospho-glucuronosyltransferases Expressed in Endometrium J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5222 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, M. S. Mayo, W. E. Burak Jr., J. A. O'Shaughnessy, K. S. Albain, D. M. Hyams, G. T. Budd, et al. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator Clin. Cancer Res., August 15, 2004; 10(16): 5403 - 5417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-S. Furberg, M. B. Veierod, T. Wilsgaard, L. Bernstein, and I. Thune Serum High-Density Lipoprotein Cholesterol, Metabolic Profile, and Breast Cancer Risk J Natl Cancer Inst, August 4, 2004; 96(15): 1152 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Somboonporn and S. R. Davis Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women Endocr. Rev., June 1, 2004; 25(3): 374 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Martino, J. Costantino, M. McNabb, J. Mershon, K. Bryant, T. Powles, and R. J. Secrest The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials Oncologist, April 1, 2004; 9(2): 116 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Endogenous Hormones and Breast Cancer Collaborativ Free Estradiol and Breast Cancer Risk in Postmenopausal Women: Comparison of Measured and Calculated Values Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1457 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Benz, C. A. Clarke, and D. H. Moore II Geographic Excess of Estrogen Receptor-Positive Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1523 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. van Gils, N. C. Onland-Moret, M. Roest, P. A. H. van Noord, and P. H. M. Peeters The V89L Polymorphism in the 5-{alpha}-Reductase Type 2 Gene and Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1194 - 1199. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yu, X.-O. Shu, B. D. L. Li, Q. Dai, Y.-T. Gao, F. Jin, and W. Zheng Joint Effect of Insulin-like Growth Factors and Sex Steroids on Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1067 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Endogenous Hormones Breast Cancer Collaborative Gr Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women J Natl Cancer Inst, August 20, 2003; 95(16): 1218 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Piccart, L. M. Parker, and K. I. Pritchard Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer Ann. Onc., July 1, 2003; 14(7): 1017 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Miller and J. S. Hunt Female Sexual Dysfunction: Review of the Disorder and Evidence for Available Treatment Alternatives Journal of Pharmacy Practice, June 1, 2003; 16(3): 200 - 208. [Abstract] [PDF]
|
|
|
|
|
|
J. F. Dorgan, S. A. Hunsberger, R. P. McMahon, P. O. Kwiterovich Jr., R. M. Lauer, L. Van Horn, N. L. Lasser, V. J. Stevens, L. A. Friedman, J. A. Yanovski, et al. Diet and Sex Hormones in Girls: Findings From a Randomized Controlled Clinical Trial J Natl Cancer Inst, January 15, 2003; 95(2): 132 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Col, R. J. Goldberg, R. K. Orr, J. K. Erban, J. M. Fortin, and R. T. Chlebowski Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model Med Decis Making, October 1, 2002; 22(5): 386 - 393. [Abstract] [PDF]
|
|
|
|
 |
|
 A R P Walker With recent changes in environmental factors among Africans in South Africa, how have cancer occurrences been affected? Perspectives in Public Health, September 1, 2002; 122(3): 148 - 155. [Abstract] [PDF]
|
|
|
|
|
|
L. S. Kinsinger, R. Harris, S. H. Woolf, H. C. Sox, and K. N. Lohr Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 2, 2002; 137(1): 59 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Grady A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy JAMA, April 24, 2002; 287(16): 2130 - 2137. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz, S. A. Castellon, and D. H. S. Silverman Estrogen, Tamoxifen, and the Brain J Natl Cancer Inst, April 17, 2002; 94(8): 547 - 549. [Full Text] [PDF]
|
|
|
|
|
|
The Endogenous Hormones and Breast Cancer Collabor Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies J Natl Cancer Inst, April 17, 2002; 94(8): 606 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cummings, T. Duong, E. Kenyon, J. A. Cauley, M. Whitehead, K. A. Krueger, and for the Multiple Outcomes of Raloxifene Evaluation Serum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene JAMA, January 9, 2002; 287(2): 216 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mandelblatt, K. R. Yabroff, W. Lawrence, B. Yi, G. Orosz, H. G. Bloom, C. B. Schecther, M. Extermann, L. Balducci, W. Satadano, et al. Screening Mammography in Elderly Women JAMA, June 28, 2000; 283(24): 3202 - 3204. [Full Text] [PDF]
|
|
|
|
|
|
H. Yu, E. P. Diamandis, and B. Hoffman Elevated Estradiol and Testosterone Levels and Risk for Breast Cancer Ann Intern Med, November 2, 1999; 131(9): 715 - 715. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cummings, S. Eckert, K. A. Krueger, D. Grady, T. J. Powles, J. A. Cauley, L. Norton, T. Nickelsen, N. H. Bjarnason, M. Morrow, et al. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial JAMA, June 16, 1999; 281(23): 2189 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. King, R. L. Sharp, M. D. Vukovich, G. A. Brown, T. A. Reifenrath, N. L. Uhl, and K. A. Parsons Effect of Oral Androstenedione on Serum Testosterone and Adaptations to Resistance Training in Young Men: A Randomized Controlled Trial JAMA, June 2, 1999; 281(21): 2020 - 2028. [Abstract] [Full Text] [PDF]
|
|
